, Tracking Stock Market Picks
Enter Symbol:
Ampio Pharmaceuticals Inc (AMPE) [hlAlert]

down 33.33 %

Ampio Pharmaceuticals Inc (AMPE) rated Buy with price target $11 by Aegis Capital

Posted on: Tuesday,  Sep 25, 2012  8:25 AM ET by Aegis Capital

Aegis Capital rated Buy Ampio Pharmaceuticals Inc (AMEX: AMPE) on 09/25/2012, when the stock price was $4.29. Since
then, Ampio Pharmaceuticals Inc has lost 33.33% as of 08/27/2015's recent price of $2.86.
If you would have followed this Aegis Capital's recommendation on AMPE, you would have lost 33.33% of your investment in 1066 days.

Ampio Pharmaceuticals, Inc. (Ampio Pharmaceuticals), formerly Chay Enterprises, Inc., develops drugs for metabolic disease, eye disease, kidney disease, inflammation and CNS disease. The Company's product pipeline includes new uses for approved drugs and new molecular entities (NMEs) for therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and central nervous system (CNS) disease. Ampio Pharmaceuticals' pipeline focuses on drugs with the potential to be safe and effective for human use. Optina is an oral drug being developed as a new treatment for diabetic retinopathy and diabetic macular edema. Vasaloc is being developed as an existing oral drug that will be a new treatment for diabetic nephropathy. In March 2010, the Company announced that it has merged with DMI Life Sciences, Inc to form Ampio Pharmaceuticals, Inc.

Aegis Capital
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/17/2014 10:25 AM Buy
6.24 16.00
as of 12/31/2012
1 Week up  5.89 %
1 Month down  -3.49 %
3 Months down  -7.94 %
1 YTD down  -16.31 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/25/2012 8:25 AM Buy
4.29 11.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy